Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 108-118

  Moraes, Maria Carolina S ^a   de Andrade, Annabel Quinet ^a,b   Carvalho, Helotonio ^c   Guecheva, Temenouga ^d   Agnoletto, Mateus H ^d   Henriques, João A P ^d   Sarasin, Alain ^b   Stary, Anne ^b   Saffi, Jenifer ^d,e   Menck, Carlos F M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Gustave Roussy Comprehensive Cancer Institute   (France)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

DNA polymerase eta (pol eta); DNA repair; Doxorubicin; LY294002; XPA; XPV

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DNA; DNA DIRECTED DNA POLYMERASE ETA; DOXORUBICIN; HISTONE H2AX; PHOSPHATIDYLINOSITOL KINASE; PHOSPHATIDYLINOSITOL KINASE RELATED KINASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELLS, CULTURED; CHROMONES; DNA DAMAGE; DNA REPAIR; DNA-DIRECTED DNA POLYMERASE; DOXORUBICIN; HISTONES; HUMANS; MORPHOLINES; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 82355191713     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.019     Document Type: Article

References (40)

1. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
2. Friesen C., Uhl M., Pannicke U., Schwarz K., Miltner E., Debatin K.M. DNA-ligase IV and DNA-PK play a critical role in deficient caspases activation in apoptosis-resistant cancer cells using doxorubicin. Mol. Biol. Cell 2008.
3. Costa R.M., Chigancas V., Galhardo Rda S., Carvalho H., Menck C.F. The eukaryotic nucleotide excision repair pathway. Biochimie 2003, 85:1083-1099.
4. Park C.J., Choi B.S. The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. Febs J. 2006, 273:1600-1608.
5. Gratchev A., Strein P., Utikal J., Sergij G. Molecular genetics of Xeroderma pigmentosum variant. Exp. Dermatol. 2003, 12:529-536.
6. Carvalho H., Garrido L.M., Furlan R.L., Padilla G., Agnoletto M., Guecheva T., Henriques J.A., Saffi J., Menck C.F. DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells. Cancer Chemother. Pharmacol. 2010, 65:989-994.
7. Saffi J., Agnoletto M.H., Guecheva T.N., Batista L.F., Carvalho H., Henriques J.A., Stary A., Menck C.F., Sarasin A. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair (Amst) 2010, 9:40-47.
8. Abdul-Ghani R., Serra V., Gyorffy B., Jurchott K., Solf A., Dietel M., Schafer R. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006, 25:1743-1752.
9. Wang Y.A., Johnson S.K., Brown B.L., McCarragher L.M., Al-Sakkaf K., Royds J.A., Dobson P.R. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int. J. Cancer 2008, 123:1536-1544.
10. Proietti De Santis L., Balajee A.S., Lorenti Garcia C., Pepe G., Worboys A.M., Palitti F., p53 Inhibition of p21 and Bax by pifithrin-alpha does not affect UV induced apoptotic response in CS-B cells. DNA Repair (Amst) 2003, 2:891-900.
11. Xing J.Z., Zhu L., Gabos S., Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol. In Vitro 2006, 20:995-1004.
12. Boyd J.M., Huang L., Xie L., Moe B., Gabos S., Li X.F. A cell-microelectronic sensing technique for profiling cytotoxicity of chemicals. Anal. Chim. Acta 2008, 615:80-87.
13. Kute T.E., Savage L., Stehle J.R., Kim-Shapiro J.W., Blanks M.J., Wood J., Vaughn J.P. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol. Immunother. 2009, 58:1887-1896.
14. Bapat A., Glass L.S., Luo M., Fishel M.L., Long E.C., Georgiadis M.M., Kelley M.R. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J. Pharmacol. Exp. Ther. 2010, 334:988-998.
15. Sijbers A.M., van Voorst Vader P.C., Snoek J.W., Raams A., Jaspers N.G., Kleijer W.J. Homozygous R788W point mutation in the XPF gene of a patient with xeroderma pigmentosum and late-onset neurologic disease. J. Invest. Dermatol. 1998, 110:832-836.
16. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269:5241-5248.
17. Rosenzweig K.E., Youmell M.B., Palayoor S.T., Price B.D. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 1997, 3:1149-1156.
18. Izzard R.A., Jackson S.P., Smith G.C. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 1999, 59:2581-2586.
19. Hall-Jackson C.A., Cross D.A., Morrice N., Smythe C. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 1999, 18:6707-6713.
20. Stiff T., O'Driscoll M., Rief N., Iwabuchi K., Lobrich M., Jeggo P.A. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004, 64:2390-2396.
21. Hiom K. DNA repair: how to PIKK a partner. Curr. Biol. 2005, 15:R473-475.
22. Lempiainen H., Halazonetis T.D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28:3067-3073.
23. Bernt K.M., Steinwaerder D.S., Ni S., Li Z.Y., Roffler S.R., Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002, 62:6089-6098.
24. Graat H.C., Witlox M.A., Schagen F.H., Kaspers G.J., Helder M.N., Bras J., Schaap G.R., Gerritsen W.R., Wuisman P.I., van Beusechem V.W. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J. Cancer 2006, 94:1837-1844.
25. Keizer H.G., Pinedo H.M., Schuurhuis G.J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 1990, 47:219-231.
26. Cutts S.M., Swift L.P., Rephaeli A., Nudelman A., Phillips D.R. Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol. Cancer Ther. 2003, 2:661-670.
27. Kurz E.U., Douglas P., Lees-Miller S.P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 2004, 279:53272-53281.
28. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006, 66:4863-4871.
29. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
30. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:9053-9058.
31. Spencer D.M., Bilardi R.A., Koch T.H., Post G.C., Nafie J.W., Kimura K., Cutts S.M., Phillips D.R. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat. Res. 2008, 638:110-121.
32. Livneh Z., Ziv O., Shachar S. Multiple two-polymerase mechanisms in mammalian translesion DNA synthesis. Cell Cycle 2010, 9:729-735.
33. Kawamoto T., Araki K., Sonoda E., Yamashita Y.M., Harada K., Kikuchi K., Masutani C., Hanaoka F., Nozaki K., Hashimoto N., Takeda S. Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis. Mol. Cell 2005, 20:793-799.
34. McIlwraith M.J., Vaisman A., Liu Y., Fanning E., Woodgate R., West S.C. Human DNA polymerase eta promotes DNA synthesis from strand invasion intermediates of homologous recombination. Mol. Cell 2005, 20:783-792.
35. Betous R., Rey L., Wang G., Pillaire M.J., Puget N., Selves J., Biard D.S., Shin-ya K., Vasquez K.M., Cazaux C., Hoffmann J.S. Role of TLS DNA polymerases eta and kappa in processing naturally occurring structured DNA in human cells. Mol. Carcinog. 2009, 48:369-378.
36. Rey L., Sidorova J.M., Puget N., Boudsocq F., Biard D.S., Monnat R.J., Cazaux C., Hoffmann J.S. Human DNA polymerase eta is required for common fragile site stability during unperturbed DNA replication. Mol. Cell. Biol. 2009, 29:3344-3354.
37. Auclair Y., Rouget R., Belisle J.M., Costantino S., Drobetsky E.A. Requirement for functional DNA polymerase eta in genome-wide repair of UV-induced DNA damage during S phase. DNA Repair (Amst) 2010, 9:754-764.
38. Soria G., Belluscio L., van Cappellen W.A., Kanaar R., Essers J., Gottifredi V. DNA damage induced Pol eta recruitment takes place independently of the cell cycle phase. Cell Cycle 2009, 8:3340-3348.
39. Chen Y.W., Cleaver J.E., Hanaoka F., Chang C.F., Chou K.M. A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents. Mol. Cancer Res. 2006, 4:257-265.
40. Safra T., Lucia B., Nicoletto M.O., Rolnitzky L., Pelles-Avraham S., Geva R., Donach M.E., Curtin J., Novetsky A., Grenader T., Lai W.C., Gabizon A.A., Boyd L., Muggia F.M. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol. Cancer Ther. 2011.